The FDA’s Harmful Restrictions on Two New COVID Drugs

Source: Cato Institute
by Jeffrey A Singer & Josh Bloom

“The Food and Drug Administration recently granted Emergency Use Authorization (EUA) to Paxlovid and molnupiravir, two lifesaving, direct‐​acting antiviral drugs that are effective in preventing both hospitalization and death of people who have contracted COVID-19. They are effective against all variants so far, including omicron, which is capable of infecting people regardless of whether they are non‐​vaccinated or fully vaccinated. Unfortunately, two requirements that the agency put in place in authorizing these drugs will all but guarantee that most people who need them will not be able to get them in time. And time is of the essence since the drugs are only effective when taken within five days of initial symptoms.” (01/13/22)